-
HitGen’s Vernalis Subsidiary Collaborates with Unison Medicines on Undruggable Bacterial Target
•
China’s HitGen Inc. (SHA: 688222) announced a strategic research collaboration between its wholly owned subsidiary, Vernalis Research, and U.S.-based Unison Medicines Inc., targeting an undisclosed bacterial pathogen previously deemed “undruggable.” The partnership leverages Vernalis’ drug discovery expertise to design small-molecule therapies, with Unison funding all R&D activities and sharing downstream…
